Shorts

0:39
Looking Beyond Genomics in Precision Medicine for Cancer Care
7 months ago

1:29
Spotlighting Imaging/Therapuetic Advances Hormone Sensitive Prostate Cancer
7 months ago
by
Ben Garmezy, MD(+1 more)

0:30
Dosing Considerations for Optimizing Ruxolitinib Efficacy in Myelofibrosis
7 months ago
by
Francesca Palandri, MD, PhD

1:22
Highlighting Advances in Localized Therapy for Genitourinary Cancers
7 months ago
by
Manojkumar Bupathi, MD, MS(+3 more)

1:02
Advancing Radioligand Therapy and Imaging Criteria in Prostate Cancer
7 months ago
by
Benjamin Garmezy, MD(+1 more)

0:53
Offering Hope for Relapsed Brain Metastatic ES-SCLC With Tarlatamab
7 months ago
by
Bingnan Zhang, MD, MBA

0:35
Outlining Chronic Myeloid Leukemia Advancements Through the Decades
7 months ago
by
Jorge E. Cortes, MD

1:30
Optimizing Care Through Multidisciplinary Collaboration in GU Cancers
7 months ago
by
Benjamin Garmezy, MD(+1 more)

0:34
Managing Narcotic Use in Perioperative CRC Care
8 months ago
by
Ronald Bleday, MD

1:30
Discussing Sexual Health in Oncologic Practice
8 months ago
by
Micheal William Kendall, MD

1:17
Managing Cancer-Related Adverse Effects Through Nutrition and Wellness
8 months ago
by
Denise B. Reynolds, RD

1:19
Bridging the Psycho-Oncology Gap in Body Image Management
8 months ago
by
Daniel C. McFarland, DO

1:29
Challenging Negative Body Image Language in Psycho-Oncology
8 months ago
by
Michelle Fingeret, PhD

1:16
Expanding Early Phase Trial Access Through START
8 months ago
by
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer
2
Targeting KRAS in Pancreatic Cancer: What is Daraxonrasib’s Mechanism of Action?
3
FDA ODAC Votes Yes to Capivasertib for PTEN-Deficient Metastatic HSPC
4
FDA Grants Priority Review to Tislelizumab/Zanidatamab in 1L HER2+ Gastric Cancers
5
